# Ionis Pharmaceuticals, Inc. (IONS) FY2026 Q2 P&L / Income Statement

- Company: Ionis Pharmaceuticals, Inc. (IONS)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-29, accession number 0000874015-26-000251
- Page: https://plicit.ai/financials/ions/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/ions-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Arrangement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 267,949,000 US dollars
- **Cost of sales**: 2,739,000 US dollars
- **Gross profit (calculated)**: 265,210,000 US dollars
- **Operating expenses (calculated)**: 367,503,000 US dollars
- **Income (loss) from operations**: negative 102,293,000 US dollars
- **Other income (expense), net (calculated)**: negative 11,089,000 US dollars
- **Income (loss) before income tax benefit (expense)**: negative 113,382,000 US dollars
- **Income tax benefit (expense)**: 1,264,000 US dollars
- **Net income (loss)**: negative 114,646,000 US dollars
- **Collaborative Agreement Revenue**: 133,137,000 US dollars
- **DAWNZERA Sales, Net**: 26,565,000 US dollars
- **Other Commercial Revenue**: 11,526,000 US dollars
- **Other Royalties**: 6,036,000 US dollars
- **TRYNGOLZA Sales, Net**: 4,574,000 US dollars
- **WAINUA Joint Development Revenue**: 16,189,000 US dollars
- **Salanersen - Biogen Collaboration2017 Spinal Muscular Atrophy Member**: 45,000,000 US dollars
- **Sapablursen - Ono**: 20,000,000 US dollars
- **Undisclosed (calculated)**: 4,922,000 US dollars
- **Research, development and patent**: 217,107,000 US dollars
- **Selling, general and administrative**: 150,396,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Arrangement

- Page: https://plicit.ai/financials/ions/fy2026-q2-income-statement/revenue-by-arrangement
- Chart image: https://plicit.ai/charts/ions-fy2026-q2-revenue-by-arrangement-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 267,949,000 US dollars
- **Cost of sales**: 2,739,000 US dollars
- **Gross profit (calculated)**: 265,210,000 US dollars
- **Operating expenses (calculated)**: 367,503,000 US dollars
- **Income (loss) from operations**: negative 102,293,000 US dollars
- **Other income (expense), net (calculated)**: negative 11,089,000 US dollars
- **Income (loss) before income tax benefit (expense)**: negative 113,382,000 US dollars
- **Income tax benefit (expense)**: 1,264,000 US dollars
- **Net income (loss)**: negative 114,646,000 US dollars
- **2018 Neurology**: 15,000,000 US dollars
- **Biogen**: 133,866,000 US dollars
- **Undisclosed (calculated)**: 119,083,000 US dollars
- **Research, development and patent**: 217,107,000 US dollars
- **Selling, general and administrative**: 150,396,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service

- Page: https://plicit.ai/financials/ions/fy2026-q2-income-statement/revenue-by-product-and-service
- Chart image: https://plicit.ai/charts/ions-fy2026-q2-revenue-by-product-and-service-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 267,949,000 US dollars
- **Cost of sales**: 2,739,000 US dollars
- **Gross profit (calculated)**: 265,210,000 US dollars
- **Operating expenses (calculated)**: 367,503,000 US dollars
- **Income (loss) from operations**: negative 102,293,000 US dollars
- **Other income (expense), net (calculated)**: negative 11,089,000 US dollars
- **Income (loss) before income tax benefit (expense)**: negative 113,382,000 US dollars
- **Income tax benefit (expense)**: 1,264,000 US dollars
- **Net income (loss)**: negative 114,646,000 US dollars
- **Product Sales, Net**: 31,139,000 US dollars
- **Royalty Revenue**: 75,958,000 US dollars
- **Other Commercial Revenue**: 11,526,000 US dollars
- **Collaborative Agreement Revenue**: 133,137,000 US dollars
- **WAINUA Joint Development Revenue**: 16,189,000 US dollars
- **Research, development and patent**: 217,107,000 US dollars
- **Selling, general and administrative**: 150,396,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.